9 Meters Biopharma, Inc. (NASDAQ:NMTR) shares surged 18.56 to $0.89 in the post-market session after the Company has announced that it has closed its previously announced underwritten public offering of 53,076,924 shares of its common stock, inclusive of the full over allotment option exercised by the underwriters for the price of $0.65 per share.
About $32 million was received by the Company in net proceeds from the public offering, after deducting underwriting discounts and commissions and offering expenses payable by 9 Meters. This offering will provide additional funds to advance the clinical development of NM-002 for the treatment of short bowel syndrome, the continued clinical development of larazotide for the treatment of celiac disease, and for working capital and general corporate purposes.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Oppenheimer & Co., Inc. was the lead manager for the offering while Brookline Capital Markets, a division of Arcadia Securities, LLC, served as a co-manager for the offering.
